1Department of Molecular Biology, University of Okara, Punjab, 53600, Pakistan.
2Department of Biochemistry, Faculty of Life Science, University of Okara, Punjab, 53600, Pakistan
Conjunctival inflammation affects millions globally and can be triggered by microbial infections, allergens, or genetic factors. This study focuses on specific SNPs in the IL-4 gene, linked to pink eye susceptibility. Using In-Silico tools, 15 SNPs were identified as potentially damaging to IL-4 protein, with the R139G, A118G, R112C, and R139W variants showing probable damage on high RMSD values, as highlighted by SAVESV6.1. Structural analysis using HOPE predicted that the R139W mutation may be structurally bigger than the IL-4 wild type, while other variants were damaging to protein stability and function. Molecular docking studies with PyRx screened 25 small molecules for interactions with IL-4. Compounds such as Ioniflavone, Meridine, Palbociclib, Pyranoamentoflavone, Ramipril, and Tetracycline demonstrated strong binding affinities with IL-4, suggesting potential therapeutic efficacy. Visualization through Discovery Studio revealed differences in residue interactions, hydrogen bonds, and hydrophilic interactions between the wild-type and mutant forms, indicating that these SNPs could alter IL-4 structure and binding. These findings suggest that genetic variants in IL-4 may play a role in pink eye susceptibility and open avenues for developing targeted therapies. Their potential in targeting IL-4-related pathways further supports their use in addressing the immune component of conjunctivitis. However, each compound would require further clinical and pharmacological evaluation to confirm efficacy and safety for ophthalmic use. Further laboratory and clinical studies are essential to validate these results and explore personalized treatments for pink eye based on IL-4 genetic profiles.
Interleukin-4 (IL-4) is a type I pleiotropic cytokine known for its four-?-helical bundle structure and its wide-ranging effects on different cell types, which is significant in both the innate and adaptive immune responses. Initially, B and T cells were identified as the primary targets affected by IL-4, highlighting its significance in immune regulation. In 1982, IL-4 was first discovered by Ellen Vitetta and her research team, with additional contributions by Maureen Howard and William E. Paul, who also helped characterize its functions [1]. In humoral immunity, it directs B-cells to produce IgE while inhibiting Th1 cytokines (IFN-gamma and IL-2). This change highlights the significance IL-4 is for fostering a Th2-mediated, antibody-focused response, which is required for controlling extracellular infections and allergy responses [2]. The IL-4 receptor is widely distributed across various organs, including the brain, fibroblasts, endothelial cells, epithelial cells, muscles, and liver, where it regulates immune functions. Genetic mutations in IL-4 and IL-4R genes can alter protein expression and activity, potentially influencing susceptibility or resistance to infectious diseases, rheumatoid arthritis, asthma, and atopy [3]. Elevated IL-4 levels are observed in seasonal allergic conjunctivitis patients and vernal keratoconjunctivitis, underscoring its significant role in these allergic eye conditions [4]. Conjunctival inflammation is frequently brought on by infections, allergies, or irritants, resulting in pink eye (conjunctivitis), which is characterized by redness in the eyes. Ocular discomfort, impaired vision, and light sensitivity are among the symptoms. Adenoviruses are frequently responsible for viral conjunctivitis [5], and are accompanied by fever, lymphadenopathy (especially preauricular), pharyngitis, and upper respiratory tract infections [6].
Moreover, common microbes responsible for bacterial conjunctivitis include Staphylococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Among these, H. influenzae, particularly non-typeable strains accounting for about 70% of cases [7] . Common signs of bacterial conjunctivitis include red eyes and a thick, mucopurulent discharge, often green or yellow [8]. Allergic conjunctivitis is a hypersensitivity reaction triggered by airborne allergens like pollen, dander, dust, and mold. It occurs when mast cells degranulate in response to an IgE-mediated reaction, releasing histamine and other inflammatory mediators. This condition peaks in young people between the ages of 15 and 18, affecting about 20% of them [9]. Similar to viral conjunctivitis, allergic conjunctivitis may show a follicular appearance of the tarsal conjunctiva, characterized by small bumps or nodules on the inner eyelid surface, along with watery discharge during clinical examination [10] Allergic conjunctivitis may not always show the typical symptoms, while blepharitis and meibomian gland dysfunction can present eye irritation and discomfort [11]. The IL-4 promotes the differentiation of naive T cells into Th2 cells, which boosts the production of immunoglobulin E (IgE) and other cytokines that drive allergic reactions and inflammation in the conjunctiva [12].
The IL-4 gene is located on human chromosome 5q31-q33 region and comprises 4 exons and 3 introns, with the exons encoding its functional domains. It is primarily produced by activated T cells, mast cells, basophils, and eosinophils that promote Th2 cell differentiation and stimulate B cell proliferation and class switching to IgE, playing a key role in humoral immunity and allergic responses. Immune responses and vulnerability to infections can be impacted by variations in the IL-4 gene [13]. The c.-589C>T (rs2243250) is located in the IL4 promoter region and shows notable differences in frequency between patients with viral conjunctivitis and healthy individuals [14]. The presence of the T allele may increase susceptibility to viral infections by altering IL-4 expression, potentially compromising immune responses [3]. The IL-4R variant rs1805010 (c.223A>G) was also analyzed for viral conjunctivitis, but no significant differences in its frequency were observed between affected patients and healthy controls [14].
It regulates B cell differentiation into plasma cells and promotes the proliferation of T and B cells. It induces B cells to switch to IgE production and enhances MHC class II expression. The IL-4 exposure also reduces the IL12 production, IFN?, and macrophages by dendritic cells and elevated IL-4 levels can lead to the development of allergic reactions [15]. In extravascular tissues, IL-4 promotes the activation of macrophages into M2 cells, which aid in tissue repair and immune regulation, while inhibiting M1 cells, which are involved in inflammation and host defense. Pathological inflammation decreases as M2 macrophages and the release of IL-10 and TGF-? increase, activated M2 cells produce substances (arginase, proline, polyamines, and TGF-?) that are major contributors to wound healing and fibrosis [16]. Furthermore, IL-4 variants significantly impact human health by influencing immune responses related to eye infections, particularly viral conjunctivitis. This study explored the IL-4 protein using several bioinformatics approaches to predict pathogenic coding variants and evaluate their potential effects on disease. We performed a functional analysis to assess the variant's impact on protein stability and function. The 3D structure of IL-4 was predicted, and we analyzed the conformational changes caused by mutations. Additionally, blind docking studies were conducted to investigate Protein-Ligand interactions, and the results were visualized to assess binding affinities and potential mechanisms. This comprehensive approach enhances our understanding of IL-4 role in pink eye disease.
Figure 1. Schematic study of the complete overflow of the current study
2.1. Variant collection
We collected data on the human IL-4 gene from the National Center for Biotechnology Information (NCBI) (https://www.ncbi), GnomAD (https://gnomad.broadinstitute.org), Ensembl (http://asia.ensembl.org/Homo_sapiens/Gene/Summary), and the NCBI dbSNP database, which provided information on IL-4 gene variants. UniProtKB (http://www.uniprot.org/uniprot) was used to acquire the protein sequence in FASTA format. A schematic overview of the study workflow is provided in Figure 1.
2.2. Functional analysis of coding IL-4 variants
2.2.1. SNPnexus
We employed SNPnexus (https://www.snp-nexus.org) for functional predictions of IL-4 gene variants. The tool utilized rsIDs extracted from the dbSNP database as query inputs to assess the potential functional impacts of specific SNPs [17]. Sorting Intolerant from Tolerant (SIFT) tool based on sequence homology, evaluates mutation impacts on protein function. Mutations with a SIFT score of < 0.05 are predicted to be detrimental, while those with a score >0.05 are considered tolerable [18]. Polymorphism Phenotyping (PolyPhen) evaluates these variants based on structural data or a combination of sequence and structural information to predict their impact on protein function [18].
2.2.2. Polymorphism Phenotyping V2
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) played a crucial role in our investigation, enabling us to predict the potential implications of amino acid changes on protein structure and function. We entered our protein sequence, database ID/accession number, and details on amino acid changes into the server. Additionally, it provides a count score, with a value of 1 indicating the probable damage, along with predictions about the potential impact of missense variants on protein function [19].
2.2.3. Protein Analysis through Evolutionary relationship
PANTHER (http://pantherdb.org/tools/csnpScoreForm.jsp) predicts the functional impact of missense variants based on molecular activities, protein interactions, and evolutionary relationships. It calculates position-specific evolutionary conservation (PSEC) scores by aligning related proteins in structure and evolution. The prediction is based on the protein sequence and amino acid changes. The results are classified into three categories, probably damaging, possibly damaging, or probably benign based on evolutionary time and protein alignment data [20].
2.2.4. PredictSNP
PredictSNP (https://loschmidt.chemi.muni.cz/predictsnp1) combines data from multiple sources to predict the impact of a single amino acid change. By integrating various tools, it provides a more efficient and accurate consensus prediction compared to individual prediction methods [21].
2.3. Association of disease-causing SNPs
2.3.1. Single nucleotide polymorphism & Gene Ontology
SNPs & GO (https://snps.biofold.org/snps-and-go/snps-and-go.html) uses a novel framework to predict whether a mutation is associated with disease, integrating genetic data, protein sequence, and Gene Ontology (GO) terms, along with 3D structural information. The tool classifies mutations as disease-associated if the probability score >0.5, and neutral < 0.5 while input files include FASTA sequences and protein variants [22].
2.3.2. Meta-SNP
Meta SNP (https://snps.biofold.org/meta-snp) is a meta-predictor that uses a random forest method to classify mutations as either 'Disease' or 'Neutral.' It is designed to detect disease-causing single nucleotide variations (nsSNVs), offering the potential for early detection and classification of harmful genetic variations, which is a promising development in genomics [23].
2.3.3. SuSPect
SuSPect (http://www.sbg.bio.ic.ac.uk/suspect) combines annotation and sequence-based approaches to prioritize disease-candidate genes. By leveraging multiple lines of evidence, it enhances performance in scoring genes quickly and efficiently, while minimizing the impact of annotation bias, making it a valuable tool in genomic research for identifying disease-related genes [24].
2.4. Consequences of nsSNP on Protein Stability
2.4.1. iStable
The iStable server (http://predictor.nchu.edu.tw/iStable) predicts changes in protein stability by using either sequence or structure information as input. It integrates results from five different prediction tools, combining various methods developed by different teams to offer a more comprehensive and accurate assessment of potential changes in protein stability [25].
2.4.2. MUpro
The MUpro server (http://mupro.proteomics.ics.uci.edu) predicts the impact of single-site mutations on protein stability using machine learning tools, including neural networks and support vector machines. MUpro predictions provide the energy change (DDG), the direction of that change, and a confidence score (ranging from -1 to 1) to indicate the accuracy of the stability prediction [26].
2.5. Structural Integration of IL4
2.5.1. IL4 template prediction
The SWISS-MODEL server (https://swissmodel.expasy.org) predicts protein 3D structures using sequence data. By submitting a FASTA sequence, the server aligns it with templates from the UniProtKB proteome to generate a model. The quality of the resulting structure is assessed using various metrics, such as the Ramachandran Plot, the QMEAN score and the MolProbity score. Moreover, the server provides annotations with experimental data, enabling researchers to select the most reliable model for further analysis [27].
2.5.2. Model Validation and refinement
The QMEAN method (https://swissmodel.expasy.org/qmean/help) tool was used for qualitative model energy analysis. It evaluates the quality of protein models by comparing their z-scores to reference structures of similar size in the Protein Data Bank (PDB). This clustering-based approach provides an empirical solution, helping to assess the reliability of models by structural properties and their alignment with known reference data [28]. The 3D protein models were further assessed using the Structure Validation Server v6.1 (https://saves.mbi.ucla.edu), which provided an evaluation of the model's z-score and identified potential structural defects. This server offers a detailed analysis, helping to confirm the accuracy and stability of the selected model by highlighting any issues that could impact its reliability [29].
2.5.3. Template modeling alignment
The TM-align (https://zhanggroup.org/TM-align) is used to compare native and mutant protein structures by performing a residual-residual alignment. The comparison is quantified using the TM-score, which ranges between 0 and 1, and the RMSD (Root Mean Square Deviation), which measures the variation between the native and mutated structures. The TM-score indicates the structural similarity (1 represents perfect match), while the RMSD reflects the degree of variation or deviation between the two structures [30]. PyMOL (https://pymol.org) is assessed for visualizing, analyzing, and manipulating predicted residues and evolutionary sites in protein structure [31].
The gene sequences obtained from UniProtKB for the proteins are consistent, ensuring a reliable source for further bioinformatics analysis. The PubChem IDs of the pharmaceutical compounds used in this study were sourced from the ZINC database (https://zinc.docking.org) and PubChem (http://www.ncbi.nlm.nih.gov/pccompound). These compounds were then converted into PDB format using the Discovery Studio v4.1 (https://discover.3ds.com/discovery-studio-visualizer-download) and the academic edition of PyMol (https://pymol.org) [32, 33].
The docking experiments were carried out using the freely accessible PyRx 0.8 program (https://pyrx.sourceforge.io). The process began by loading a protein in PDB format and converting it into a macromolecule. A ligand was selected and transformed using the AutoDock button. The Vina Wizard was launched by clicking the start button, followed by setting up the grid with the "maximize" option. Vina was activated by pressing the appropriate button. After sufficient time, the best docking scores for each protein-ligand pair were recorded. To analyze the ligand-protein interactions, the Discovery Studio Visualizer was used to generate 2D and 3D PNG images of the ligand and protein [34, 35].
The Mutation 3D tool (http://www.mutation3d.org) was utilized to visualize and investigate the spatial distribution of amino acid alterations on protein structures and model [36]. The HOPE Project (http://www.cmbi.ru.nl/hope/input) is a comprehensive tool designed to forecast the physical and chemical properties of proteins, and their function, hydrophobicity, and spatial structure. Users can input a single identification, such as UniProt ID, Gene/Protein Symbol, or Ensemble Transcript, into its interface [37].
3.1. Datasets
The variations in the human IL-4 gene were sourced from NCBI dbSNP, Ensembl, and GnomAD databases. Figure 2 categorizes single nucleotide polymorphism (SNP) distribution within the IL-4 gene, highlighting key genomic regions. The 3? UTR region contains 97 SNPs, and the broader UTR region has 125 SNPs. Within two distinct intronic regions, 5,133 SNPs are found in one, and 1,140 in the other. The coding region includes 5,616 SNPs, divided into 97 exonic, 323 missense, and 160 synonymous SNPs. Additionally, there are 1,237 SNPs in non-coding regions. The 3? downstream region contains 977 SNPs, while the 5? upstream region has 775 SNPs, including 28 SNPs within the 5? UTR. This detailed classification offers a comprehensive view of SNP distribution across the IL-4 gene. The missense nsSNPs were chosen for further investigation, as these variants are more likely to impact protein function by causing amino acid changes, potentially altering the structure, stability, or function of the IL-4 protein. This selection focuses on identifying variations with a higher probability of functional relevance, which may provide insights into the gene's role in disease mechanisms.
Figure 2. The prediction of variations is categorized into key genomic regions of IL4.
Figure 3. Bar plot of SNPs identified by a) SIFT and b) PolyPhen.
3.2. Deleterious nsSNPs In-Silico prediction
Using sequence homology of amino acids, SIFT provided predictions for a set of identified nsSNPs by revealing 261 nsSNPs as frequent, with 194 deletions projected to be deleterious and 67 deemed tolerable. PolyPhen results predicted that 57 nsSNPs were likely damaging, 38 possibly damaging, and 198 benign, as shown in Figure 3. Among these, 15 SNPs were identified as highly deleterious and selected for in-depth analysis as given in Table 1. For these 15 nsSNPs, predictions on functional impact and stability were performed using 10 different bioinformatic servers
Table 1. Prediction of 15 highly deleterious nsSNP found by SIFT and PolyPhen
Variation ID |
Variant |
Mutation |
SIFT |
Polyphen |
||
Score |
Prediction |
Score |
Prediction |
|||
rs1163858187 |
G/T |
C70F |
0 |
Deleterious |
1 |
Probably Damaging |
rs1446449750 |
C/A |
L76I |
0.01 |
Deleterious |
1 |
Probably Damaging |
rs149950065 |
C/A |
A118E |
0.01 |
Deleterious |
1 |
Probably Damaging |
rs778014138 |
G/A |
R139W |
0.01 |
Deleterious |
0.996 |
Probably Damaging |
rs199929962 |
T/C |
M144T |
0.03 |
Deleterious |
0.994 |
Probably Damaging |
rs1361163509 |
C/T |
A94T |
0.04 |
Deleterious |
0.994 |
Probably Damaging |
rs778014138 |
G/C |
R139G |
0.01 |
Deleterious |
0.993 |
Probably Damaging |
rs376367511 |
T/C |
C123R |
0 |
Deleterious |
0.99 |
Probably Damaging |
rs1444583505 |
T/C |
L7P |
0.02 |
Deleterious |
0.983 |
Probably Damaging |
rs149950065 |
C/G |
A118G |
0.02 |
Deleterious |
0.979 |
Probably Damaging |
rs775753738 |
C/T |
L110F |
0.01 |
Deleterious |
0.975 |
Probably Damaging |
rs753127489 |
C/A |
S81I |
0 |
Deleterious |
0.95 |
Probably Damaging |
rs751850550 |
G/A |
R112C |
0 |
Deleterious |
0.941 |
Probably Damaging |
rs1245723965 |
C/T |
A58V |
0.01 |
Deleterious |
0.934 |
Probably Damaging |
rs4252548 |
C/T |
R112H |
0.01 |
Deleterious |
0.922 |
Probably Damaging |
Furthermore, PolyPhen-2, PANTHER, and PredictSNP offer insights into the potential impact of mutations on IL4 protein function. Among the 15 nsSNPs analyzed, PANTHER predicted that 13 of these variants could be possibly damaging, while two (A94T and S81I) were classified as probably benign. PredictSNP results similarly identified A94T and S81I as neutral, with the remaining 13 nsSNPs likely to have deleterious effects. Moreover, PolyPhen-2 considered all 15 nsSNPs as probably damaging, as detailed in Table 2.
Table 2. Screening of functional impact of nsSNPs by PANTHER, PredictSNP & Polyphen2
Variation ID |
Mutation |
PANTHER |
Predict SNP |
Polyphen2 |
|
Prediction |
Score |
Prediction |
Prediction |
||
rs1163858187 |
C70F |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs1446449750 |
L76I |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs149950065 |
A118E |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs778014138 |
R139W |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs199929962 |
M144T |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs1361163509 |
A94T |
Probably benign |
0.19 |
Neutral |
Probably Damaging |
rs778014138 |
R139G |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs376367511 |
C123R |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs1444583505 |
L7P |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs149950065 |
A118G |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs775753738 |
L110F |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs753127489 |
S81I |
Probably benign |
0.19 |
Neutral |
Probably Damaging |
rs751850550 |
R112C |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs1245723965 |
A58V |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
rs4252548 |
R112H |
Possibly damaging |
0.5 |
Deleterious |
Probably Damaging |
3.3. Functional nsSNPs with disease
According to Table 3, SNPs & GO predicted that 14 nsSNPs analyzed are associated with disease, with only the rs1361163509 (A94T) variant considered neutral. Meta SNP analysis identified 7 nsSNPs as neutral and classified 8 as disease-related. In contrast, SuSPect classified all 15 nsSNPs as disease-related.
Table 3. Findings of disease-linked nsSNPs and their effect on IL4 stability.
Variation ID |
AA |
Suspect |
Meta SNP |
SNP & Go |
MUpro |
i-stable |
||||
Sc |
Effect |
Sc |
Sc |
Effect |
Stability |
Detal Delta |
Stability |
Conf. score |
||
rs1163858187 |
C70F |
99 |
D |
4 |
9 |
D |
Decrease |
-0.665856 |
Increase |
0.232482 |
rs1446449750 |
L76I |
84 |
D |
2 |
6 |
D |
Decrease |
-0.600843 |
Decrease |
-1 |
rs149950065 |
A118E |
69 |
D |
2 |
6 |
D |
Decrease |
-0.426898 |
Increase |
0.314662 |
rs778014138 |
R139W |
89 |
D |
2 |
8 |
D |
Decrease |
-0.669057 |
Decrease |
-1 |
rs199929962 |
M144T |
92 |
D |
3 |
9 |
D |
Decrease |
-1.643079 |
Decrease |
-0.530474 |
rs1361163509 |
A94T |
62 |
N |
8 |
1 |
N |
Decrease |
-0.334169 |
Increase |
0.317224 |
rs778014138 |
R139G |
82 |
N |
1 |
8 |
D |
Decrease |
-1.694123 |
Decrease |
-1 |
rs376367511 |
C123R |
98 |
D |
6 |
10 |
D |
Decrease |
-1.854136 |
Decrease |
-1 |
rs775753738 |
L110F |
90 |
N |
3 |
8 |
D |
Decrease |
-1.5245074 |
Increase |
-1 |
rs1444583505 |
L7P |
90 |
N |
5 |
8 |
D |
Decrease |
-1.610338 |
Decrease |
-1 |
rs753127489 |
S81I |
56 |
N |
7 |
3 |
D |
Decrease |
-0.508011 |
Decrease |
-0.290899 |
rs751850550 |
R112C |
87 |
D |
5 |
9 |
D |
Decrease |
-0.779039 |
Decrease |
-1 |
rs1245723965 |
A58V |
59 |
N |
6 |
6 |
D |
Decrease |
-0.0818102 |
Increase |
0.558775 |
rs4252548 |
R112H |
82 |
D |
5 |
9 |
D |
Decrease |
-0.967623 |
Decrease |
-0.77776 |
rs149950065 |
A118G |
69 |
N |
6 |
5 |
D |
Decrease |
-1.062422 |
Increase |
0.433026 |
* AA: Amino Acid; D: Disease; N: Neutral; Sc: Score
3.4. Protein Stability change by variations
Using the MuPro server, all 15 nsSNPs were found to reduce protein stability. In this study, i-Stable predicts changes in protein thermal stability, rs1446449750 (L76I), rs778014138 (R139W), rs199929962 (M144T), rs778014138 (R139G), rs376367511 (C123R), rs1444583505 (L7P), rs753127489 (S81I), rs751850550 (R112C), and rs4252548 (R112H) decrease thermal stability. In contrast, rs63858187 (C70F), rs149950065 (A118E), rs1361163509 (A94T), rs149950065 (A118G), rs775753738 (L110F), and rs1245723965 (A58V) increase stability as summarized in Table 3.
3.5. Modeling of IL4 protein
The reported 3D model of the IL4 protein in the NCBI database is incomplete. To address this limitation, we used the Swiss Model server to generate a more comprehensive template. Our analysis focused on assessing structural changes in the IL4 protein induced by 15 highly conserved mutations. The Mutation 3D analysis revealed that the mutations A58V, R139G, R139W, and M144T are categorized as covered mutations, while A118G, C70F, L61I, A94T, L7P, L110F, S81I, R112C, R112H, and C123R are grouped as clustered mutations, as shown in Table 4. The 3D structures of these mutations are visualized with the mutations highlighted in red and blue, as depicted in Figure 3. These structural visualizations aid in understanding the spatial distribution and potential impact of the mutations on the IL-4 protein.
Figure 3. Visual representation of IL4 model by Mutation 3D.
Out of the 15 templates from SWISS-MODEL, 93.46% matched the STML ID P51492.1A. The IL-4 protein's three-dimensional structure was accurately modeled using the Alphafold DB model of IL4-MACMU (Homo sapiens) for the query sequence, with the template P51492.1A (amino acid range: 1-153) and are visualized using PyMOL, and the final model is presented in Figure 4a. This modeling method provides a comprehensive understanding of the structural alterations caused by mutations in the IL-4 protein. Our study was further used Galaxy Refine, which significantly improved the model quality and selected Model 05 as the refined version. The modeled framework was validated using SAVES v6.1, and the secondary structure was assessed through a RAMACHANDRAN plot evaluation. The final model met all criteria set forth by potential energy calculations. As shown in Figure 4b, 98.60% of the amino acid residues in the IL-4 protein were positioned in a favorable region on the RAMACHANDRAN plot, suggesting high structural integrity. All of the anticipated outcomes are summarized in Table 4 and A118G, A139W, R112C, and R139G exhibit high RMSD values, indicating notable structural deviations.
Figure 4. IL4 protein configuration (a) 3D IL4 Structure (b) Model Quality (c) Statistics of Ramachandran Plot
Moreover, QMEAN gives QMEAN Z-score of ?0.81, which is comparable to experimental structures of similar sizes to predict model quality. A negative QMEAN Z-score indicates potential structural instability of the protein. As shown in Figure 4c, the IL-4 model is represented by a red star. All proteins on this list had their corresponding PDB files retrieved and modified using PyMOL.
Table 4. Prediction of variants effect and structure verification confirmation score
AA |
Mutation 3D |
ERRAT |
Procheck |
Verify |
TM Align |
||||
Score |
Core |
Allow |
Generously |
Disallowed |
Score |
TM Sc |
RMSD |
||
Model |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
|||
C70F |
Clustered |
89.5105 |
97.90% |
2.10% |
0.00% |
0.00% |
65.36% |
0.99538 |
0.32 |
L76I |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
63.40% |
0.9961 |
0.29 |
A118E |
Clustered |
95.6835 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99594 |
0.3 |
R139W |
Covered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
62.75% |
0.99429 |
0.36 |
A94T |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99563 |
0.31 |
R139G |
Covered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99284 |
0.41 |
C123R |
Clustered |
89.5105 |
97.90% |
2.10% |
0.00% |
0.00% |
59.48% |
0.99509 |
0.33 |
L7P |
Clustered |
94.8905 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99604 |
0.29 |
A118G |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99496 |
0.34 |
L110F |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99592 |
0.3 |
S81I |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99510 |
0.33 |
R112C |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99443 |
0.35 |
A58V |
Covered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
59.48% |
0.99563 |
0.31 |
R112H |
Clustered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99551 |
0.31 |
M144T |
Covered |
95.5882 |
97.90% |
2.10% |
0.00% |
0.00% |
64.05% |
0.99557 |
0.31 |
Figure 5. Structure of mutant IL4 protein visualized by PyMOL Program
In the present study, we docked 25 selected ligands from PubChem with both the wild-type and mutant (R139W, R139G, A118G, and R112C as given in Figure 5) forms of the IL-4 protein using the PyRx program to explore ligand-protein interactions. For each ligand, 10 unique conformations were generated, with binding affinities reported in -Kcal/mol. The docking results reveal a correlation between binding affinity and ligand activity, highlighting the effectiveness of specific compounds in interacting with IL-4 and its variants.
Table 5. Docking score of 25 ligands with wild-type and mutant IL-4 proteins.
Ligands |
P51492.1A |
R139W |
R139G |
A118G |
R112C |
Apigenin |
-6.4 |
-6.4 |
-6.3 |
-6.3 |
-6.4 |
Benazepril |
-5.6 |
-5.7 |
-5.6 |
-5.6 |
-5.7 |
Enalapril |
-5.2 |
-5.1 |
-5.8 |
-5.5 |
-5.6 |
GAG |
-4.5 |
-4.5 |
-4.5 |
-4.5 |
-4.5 |
GN8 |
-6.5 |
-6.5 |
-6.5 |
-6.5 |
-6.5 |
Ioniflavone |
-8.3 |
-8.3 |
-8.2 |
-8.3 |
-8.3 |
Meridine |
-7.4 |
-7.4 |
-7.4 |
-6.7 |
-7.3 |
Meoxipril |
-5.5 |
-5.7 |
-5.7 |
-5.7 |
-5.7 |
Palbociclib |
-7.0 |
-7.0 |
-7.0 |
-7.0 |
-7.0 |
Pyranoamentoflavone |
-8.2 |
-8.2 |
-6.9 |
-8.2 |
-8.2 |
Quinapril |
-5.7 |
-5.7 |
-5.9 |
-5.7 |
-5.7 |
Ramipril |
-6.0 |
-6.1 |
-6.8 |
-6.2 |
-6.3 |
Riluzole |
-5.6 |
-5.6 |
-5.4 |
-5.6 |
-5.6 |
Refecoxib |
-5.9 |
-5.9 |
-6.0 |
-5.8 |
-5.9 |
S-Adenosylmethionine |
-5.6 |
-5.9 |
-5.5 |
-5.8 |
-5.8 |
Saxitoxin |
-6.4 |
-6.3 |
-6.5 |
-6.4 |
-6.3 |
Sclareol |
-5.8 |
-5.9 |
-5.8 |
-5.9 |
-5.8 |
Sinularin |
-6.2 |
-6.3 |
-6.3 |
-6.1 |
-6.3 |
Tamoxifen |
-5.4 |
-5.4 |
-5.7 |
-5.9 |
-5.6 |
Tetracycline |
-7.6 |
-7.5 |
-5.4 |
-7.3 |
-7.5 |
Tetrodotoxin |
-6.4 |
-6.4 |
-5.5 |
-6.4 |
-6.4 |
Thymoquinone |
-5.4 |
-5.0 |
-5.3 |
-4.8 |
-5.4 |
Topiramate |
-5.9 |
-5.9 |
-6.0 |
-6.0 |
-6.0 |
Trandolapril |
-6.4 |
-6.3 |
-6.4 |
-6.4 |
-6.2 |
Vixotrigine |
-6.7 |
-6.4 |
-6.3 |
-6.6 |
-6.6 |
Our study on IL-4 interactions with various ligands has identified several compounds with promising therapeutic potential for conjunctivitis by targeting inflammation and infection pathways. The study highlighted five compounds Ioniflavone, Meridine, Pyranoamentoflavone, Palbociclib, Tetracycline, and Ramipril that demonstrated substantial binding affinities when docked with both the native IL-4 protein and its mutant complexes. The binding affinity scores ranged from -4.5 Kcal/mol to -8.3 Kcal/mol, as shown in Table 5. These findings underscore the potential of these compounds in effectively interacting with IL-4 and its mutant forms, suggesting promising candidates to treat eye infections (conjunctivitis). Using Discovery Studio, we visualized and predicted the interactions between each ligand and the active site of the IL-4 protein, illustrating key binding interactions and affinities as given in Figure 6. This visualization provides insight into the binding mechanisms and structural compatibility of each compound, supporting their potential efficacy as inhibitors or modulators of the IL-4 protein.
In Table 6, the IL-4 binding pocket was filled with the ligand Ioniflavone, which exhibited significant interactions with key residues through Van der Waals forces. The involved residues include TYR80, ARG77, VAL75, VAL53, THR49, LEU103, GLU134, PHE106, ASN39, SER40, ARG109, ARG112, ILE35, THR42, LYS141, GLN32, LEU31, THR30, and ILE29. Ioniflavone, a flavonoid known for its anti-inflammatory and antioxidant properties, has the potential to reduce inflammation and oxidative stress. Given these attributes, it may help alleviate conjunctivitis symptoms by modulating immune response, underscoring its potential as a therapeutic agent in treating eye infections. The docking studies revealed that the Meridine and Palbociclib ligands have strong binding affinities with IL-4 binding pocket, with several key interactions that suggest therapeutic potential in inflammation-related eye conditions as shown in Figure 6.
Moreover, Meridine showed binding through Van der Waals interactions with residues such as LEU133, THR42, ASN39, LYS141, LYS36, ILE35, GLU33, ASP111, ARG109, PHE106, and LEU114, showcases anti-inflammatory properties that may help reduce swelling and discomfort in conjunctivitis by modulating inflammatory pathways. Similarly, Palbociclib interacted with native IL-4 binding pocket residues ILE29, LEU31, GLN32, LYS36, ASN39, ILE35, ARG109, THR42, LEU140, ALA73, ARG112, LYS108, PHE106, PHE136, and LEU103 as summarized in Table 6. Although Palbociclib is primarily known as a cell cycle modulator in cancer treatments, its role in reducing immune cell proliferation could help control excessive inflammatory responses in conjunctivitis.
Moreover, Pyranoamentoflavone displayed favorable binding within the native IL-4 binding pocket, involving interactions with residues such as ALA72, LYS108, ARG77, TRP115, TYR80, and LEU133 as shown in Table 6. By inhibiting microbial growth, Pyranoamentoflavone could reduce the bacterial or viral load associated with eye infections, while its anti-inflammatory effects may alleviate symptoms and prevent tissue damage due to prolonged inflammation. Tetracycline formed interactions with several native IL-4 residues, including PHE136, LEU133, LEU107, THR42, LEU140, and LYS141 as given in Table 6. Known for its effectiveness against bacterial infections, it operates by blocking bacterial protein synthesis, as it allows for the rapid reduction of the infection, promoting tissue healing and reducing the risk of secondary complications. Lastly, Ramipril is typically used as an ACE inhibitor, its ability to modulate inflammation could make it a valuable adjunct treatment for conjunctivitis characterized by significant inflammatory responses. Moreover, mutant IL4 proteins (A118G, A139W, R112C, and R139G) highlighted the active site residues as summarized in Table 6.
Figure 5. IL4 protein with ligands show 2D interactions visualization by Discovery Studio Visualizer
These compounds present a promising range of therapeutic actions for conjunctivitis, addressing both infectious and immune-related factors. Their diverse mechanisms antimicrobial, anti-inflammatory, and immune-modulating could potentially improve the management of conjunctivitis, especially in complex cases with bacterial, viral, or inflammatory components. Future pharmacological and clinical investigations will be crucial to confirm their suitability for ophthalmic use, as well as to determine optimal dosing and safety profiles.
Table 6. Interacting active residues of IL4 protein with ligands obtained from docking studies
Protein- Ligands |
Hydrophilic interactions |
Hydrophobic interactions |
Stearic Hinderance |
P51492.1A- Ioniflavone |
TYR80,ARG77,VAL75,VAL53,THR49,LEU103,GLU134, PHE106, ASN39, SER40, ARG109, ARG112, ILE35, THR42, LYS141, GLN32, LEU31, THR30, ILE29 |
LEU110, PHE79 |
ASN113, THR37, IL334, GLU33, LYS36, LEU38, LEU41, LEU137, LEU133, LEU107, LEU76 |
P51492.1A- Meridine |
LEU133, THR42, ASN39, LYS141, LYS36, ILE35, GLU33, ASP111, ARG109, PHE106, LEU114 |
LEU76, LEU107 |
LEU41, LEU137,LEU38, LEU110, THR37, ILE34, ASN113 |
P51492.1A- Palbociclib |
ILE29, LEU31, GLN32, LYS36, ASN39, ILE35, ARG109, THR42, LEU140, ALA73, ARG112, LYS108, PHE106, PHE136, LEU103 |
LEU76, LEU114 |
THR30, ASN113, GLU33, ILE34, THR37, LEU38, LEU41, LEU137, LEU107, LEU110, ASP111, LEU133 |
P51492.1A- Pyranoamentoflavone |
ALA72, LYS108, ARG77, TRP115, TYR80, LEU133, PHE106, LEU103, GLU43, SER40, ARG112, MET144, LYS36, LEU31, GLN32, THR30,THR37, GLU138 |
ALA73, LEU114, LEU137, LYS141, ARG109 |
LEU76, LEU107, LEU110, ASP111, LEU140, LEU41, THR42, LEU38, ASN39, ASN113, ILE34, ILE35, GLU33 |
P51492.1A- Tetracycline |
PHE136, LEU133, LEU107, THR42, LEU140, LYS141, ASN39, MET144, GLN32, LEU31, THR30, ASP111, LEU114, ARG112, ARG109, LYS36 |
NULL |
LEU76, LEU137, LEU41, LEU38, ILE35, GLU33, ILE34, LEU110, THR37, PHE106, ASN113 |
A118G- Ioniflavone |
THR49, VAL53, LEU103, VAL75, ARG77, GLU134, PHE106, ASN39, SER40, ARG109, ARG112, ILE35, THR42, LYS141, GLN32, TYR80, LEU31, THR30, ILE29 |
LEU110, PHE79 |
LEU133, LEU137, LEU41, LEU107, LEU76, LEU38, LYS36, THR37, ILE34, GLU33, ASN113 |
A118G- Meridine |
LEU133, THR42, ASN39, LYS141, LYS36, ILE35, GLU33, ASP111, ARG109, PHE106, LEU114 |
LEU76, LEU107 |
LEU41, LEU137, LEU38, THR37, ILE34, LEU110, ASN113 |
A118G- Palbociclib |
ILE29, GLN32, LEU31, LYS36, ILE35, ASN39, THR42, LEU140, ALA73, ARG112, LYS108, PHE106, PHE103, PHE136, LEU103 |
LEU76, LEU114 |
THR30, ASN113, GLU33, ILE34, LEU41, THR37, LEU137, LEU107, LEU133, LEU10, ASP111 |
A118G- Pyranoamentoflavone |
ARG77, ALA72, LYS108, TYR80, TRP115, PHE106, LEU133, LEU103, GLU43, SER40, GLU138, THR37, GLN32, THR30, LEU31, LYS36, MET144, ARG112 |
ALA73, LEU114, LEU137, LYS141, ARG109 |
LEU76, LEU107, LEU110, ASP111, LEU140, LEU41, THR42, LEU38, ASN39, ASN113, ILE34, ILE35, GLU33 |
A118G- Tetracycline |
LEU133, PHE136,THR42, LEU140, LYS141, ASN39, MET144, LYS36, GLN32, LEU31, THR30, ASP111, LEU114, ARG112, ARG109, LEU107 |
NULL |
LEU76, LEU137, LEU41, LEU38, ILE35, GLU33, ILE34, LEU110, THR37, PHE106, ASN113 |
R139W- Ioniflavone |
TYR80, ARG77, VAL75, VAL53, THR49, LEU103, GLU134, PHE106, ASN39, SER40, ARG109, ARG112, ILE35, THR42, LYS141, GLN32, LEU31, THR30, ILE29 |
LEU110, PHE79 |
LEU133, LEU137, LEU41, LEU107, LEU76, LEU38, LYS36, THR37, ILE34, GLU33, ASN113 |
R139W-Meridine |
LEU133, THR42, ASN39, LYS141, LYS36, ILE35, GLU33, ASP111, ARG109, PHE106, LEU114 |
LEU76, LEU107 |
LEU41, LEU137, LEU38, THR37, ILE34, LEU110, ASN113 |
R139W-Palbociclib |
ILE29, GLN32, LEU31, LYS36, ILE35, ASN39, ARG109, THR42, LEU103, PHE136, PHE106, LYS108, ARG112, LEU140, ALA73 |
LEU114, LEU76 |
LEU137, LEU107, LEU133, LEU110, ASP111, LEU41, LEU38, THR37, ASN113, GLU33, ILE34, THR30 |
R139W-Pyranoamentoflavone |
ALA72, LYS108, ARG77, TRP115, TYR80, LEU133, LEU103, GLU43, SER40, GLU138, ARG112, MET144, LYS36, LEU31, GLN32, THR37, THR30, PHE106 |
ALA73, LEU114, LEU137, LYS141, ARG109, |
LEU76, LEU107, LEU110, ASP111, LEU140, BLEU41, THR42, LEU38, ASN39, ASN113, ILE34, GLU33, ILE35 |
R139W-Tetracycline |
LEU133, PHE136, THR42, LEU107, LEU140, LYS141, ASN39, LYS36, GLN32, MET144, LEU31, THR30, ASP111, LEU114, ARG112, ARG109, |
NULL |
LEU76, LEU137, LEU41, LEU38, ILE35, GLU33, ILE34, LEU110, THR37, PHE106, ASN113 |
R112C- Ioniflavone |
THR49, GLU134, LEU103, VAL53, ARG77, TYR80, VAL75, PHE106, SER40, ASN39, ARG109, CYS112, THR42, ILE35, LYS141, GLN32, LEU31, THR30, ILE29 |
LEU110, PHE79 |
LEU41, LEU137, LEU133, LEU76, LEU107, LEU38, LYS36, THR37, ILE34, GLU33, ASN113 |
R112C-Meridine |
LEU133, THR42, ASN39, LYS141, LYS36, ILE35, GLU33, ASP111, ARG109, PHE106, LEU114 |
LEU76, LEU107 |
LEU41, LEU137, LEU38, THR37, ILE34, LEU110, ASN113 |
R112C- Palbociclib |
ILE29, LEU31, LYS36, GLN32, ASN39, ILE35, LEU140, ALA73, CYS112, LYS108, PHE106, PHE136, LEU103, THR42, ARG109 |
LEU76, LEU114 |
THR30, ASN113, GLU33, ILE34, THR37, LEU41, LEU38,LEU107, LEU137, LEU133, LEU110, ASP111 |
R112C- Pyranoamentoflavone |
ALA72, LYS108, ARG77, TRP115, CYS112, MET144, LYS36, LEU31, GLN32, LEU31, THR30, THR37, GLU138, SER40, GLU43, LEU103, LEU133, PHE106, TYR80 |
ALA73, LEU114, LEU137, LYS141, ARG109 |
THR42, ASN39, ASN113, GLU33, LEU41, LEU38, ILE34, ILE35, LEU76, LEU107, LEU110, ASP111, LEU140 |
R112C- Ramipril |
PHE79, TYR80, PHE106, THR42, LYS141, PHE136, LYS108, ILE35, LEU31, THR30, LYS36, GLN32, ASN113, MET144, LEU114, ASP111, LEU140, ASN39 |
LEU133, LEU137, ARG109 |
LEU76, THR37, LEU107, ILE34, GLU33, LEU110, LEU38, LEU41 |
R139G- Ioniflavone |
TYR80, VAL75, ARG77, VAL53, THR49, LEU103, GLU134, PHE106, ASN39, SER40, ARG109, ARG112, ILE35, THR42, LYS141, GLN32, LEU31, THR30, ILE30 |
LEU110, PHE79 |
ASN113, LYS36, THR37, ILE34, GLU33, LEU38, LEU41, LEU137, LEU107, LEU76, LEU133 |
R139G- Meridine |
LYS36, ILE35, GLU33, LYS141, ASN39, THR42, LEU133, ASP111, ARG109, PHE106, LEU114 |
LEU76, LEU107 |
LEU41, LEU137, LEU38, LEU110, THR37, ILE34, ASN113 |
R139G- Palbociclib |
LEU103, PHE136, PHE106, LYS108, ARG112, ALA73, THR42, ARG109, ASN39, LEU140, ILE35, LYS36, GLN32, LEU31, ILE29 |
LEU114, LEU76, |
LEU107, LEU137, LEU133, LEU110, ASP111, ASN113, LEU41, GLU33, ILE34, LEU38, THR37, THR30 |
R139G- Pyranoamentoflavone |
TYR80, ALA72, LYS108, ARG77, TRP115, LEU133, LEU103, PHE106, GLU43, SER40, GLU138, THR37, GLN32, LYS36, LEU31, THR30, ARG112, MET144 |
ALA73, LEU114, LEU137, LYS141, ARG109 |
LEU76, LEU107, LEU110, ASP111, LEU140, LEU41, THR42, ASN39, LEU38, ASN113, ILE34, GLU33, ILE35 |
R139G- Tetracycline |
LEU140, THR42, PHE136, LEU133, LEU107, LYS141, ASN39, MET144, LYS36, GLN32, LEU31, THR30, ASP111, LEU114, ARG112, ARG109, |
NULL |
GLU33, ILE34, LEU110, ASN113, ILE35, LEU38, THR37, PHE106, LEU41, LEU137, LEU76 |
The HOPE server analysis hypothesized that altering a single amino acid in the IL-4 protein would significantly affect its structural and functional properties, including spatial arrangement, hydrophobicity, and both physical and chemical characteristics. We found the substitution of amino acid R139W results in a larger mutant compared to the wild-type residue, whereas the mutations R112C, R139G, and A118G lead to smaller variants as given in Table 7. In addition, R139W, R112C, R139G, and A118G show increased hydrophobicity, which may alter interactions within the protein structure and potentially affect protein folding. The analysis further suggests that the mutations R112C, R139G, and A118G are possibly damaging to the protein's stability and function. These structural changes in key regions could thus have significant implications for the IL-4 protein's biological function, potentially impacting immune signalling pathways.
Table 7. Physiochemical properties of mutant IL4 protein by HOPE Project
rsID |
Mutations |
Mutant a.a size |
SNP Location |
Polymorphism |
Amino acid properties |
rs778014138 |
R139W |
Bigger |
More hydrophobic |
NULL |
Wild-type residue is lost by this mutation. This can cause loss of interactions with other molecules. |
rs751850550 |
R112C |
Smaller |
More hydrophobic |
Possibly Damaging |
The mutant residue is smaller than the wild-type residue. This will cause a possible loss of external interactions. |
rs778014138 |
R139G |
Smaller |
More hydrophobic |
Possibly Damaging |
The charge of the wild-type residue is lost by this mutation. This can cause loss of interactions with other molecules. |
rs149950065 |
A118G |
Smaller |
More hydrophobic |
Possibly Damaging |
The mutant residue is smaller than the wild-type residue. The mutation will cause a space in the core of the protein. |
DISCUSSION
The current study comprehensively analyzed the data on disease-causing nonsynonymous single nucleotide polymorphisms (nsSNPs) in the IL-4 gene using several prediction tools, including SIFT, PolyPhen, PANTHER, PolyPhen2, SUSPECT P, MetaSNPs, MuPro, SNP&GO, iStable, and Predict SNP. Bioinformatics tools have been employed to predict the functional consequences of mutations in the IL-4 gene, revealing how changes in its structure and stability may influence disease outcomes. The IL-4 protein’s role in immune modulation is further highlighted by its effect on macrophage activation, where IL-4 induces M2 polarization, promoting tissue repair and regulating inflammation. Interleukin-4 (IL-4) plays a pivotal role in the immune system, particularly in the regulation of humoral immunity and allergic responses. It influences the differentiation of naive T cells into Th2 cells and enhances B-cell differentiation, promoting IgE production, which is crucial in allergic reactions. IL-4's effect on immune responses makes it essential in managing conditions like asthma, rheumatoid arthritis, and allergic conjunctivitis, where it drives inflammation in response to allergens or infections.
In conjunctivitis, IL-4 levels are elevated in patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis, reflecting its significant involvement in these allergic eye diseases. The gene encoding IL-4, located on chromosome 5q31-q33, undergoes various genetic mutations that affect its expression, influencing susceptibility to eye infections, especially viral conjunctivitis. For instance, the c.-589C>T polymorphism has been linked to altered IL-4 expression, potentially heightening susceptibility to infections like viral conjunctivitis, while the IL-4 receptor variant rs1805010 showed no significant association with the condition. These genetic variations underscore the impact of IL-4 in immune dysregulation and disease susceptibility. These tools helped assess the potentially detrimental effects of 15 known nsSNPs on IL-4 function and protein stability.
The PANTHER analysis identified 13 nsSNPs as potentially harmful, while two variants, A94T and S81I, were likely benign. Predict SNP similarly predicted a neutral effect for A94T and S81I, whereas PolyPhen2 classified all 15 nsSNPs as possibly damaging. Additionally, SNP&GO, SuSpect, and MetaSNP identified several of these nsSNPs as linked to disease prediction. To understand the impact on protein stability, iStable and MuPro were employed. MuPro’s analysis indicated a decrease in stability for all 15 nsSNPs, whereas iStable revealed that 9 nsSNPs caused a reduction in thermal stability, with the remaining 6 leading to stability increases. Mutation 3D mapping revealed that of these 15 mutations, 6 were mapped, 8 were clustered, and 1 remained unmapped. This analysis helped to refine understanding of the functional and structural impacts of these mutations.
Moreover, Structural assessment was performed using SWISS-MODEL, PROCHECK, QMEAN, ERRAT, verify 3D, and TM-Align, which together confirmed the model’s high-quality structure for the IL-4 protein sequence. Notably, the Ramachandran plot demonstrated the stereochemical quality of the modeled protein, with more than 90% of residues in preferred regions. SWISS-MODEL confirmed sequence conservation within the amino acid range of 1–153, and QMEAN-Z scores validated the model’s quality. Molecular docking studies were conducted using PyRx Autodock Vina to assess the binding affinities of 25 ligands with both normal and mutated IL-4 complexes. Key findings included high docking scores for the interactions between the IL-4 model and several ligands, Ioniflavone (-8.3), Meridine (-7.4), Palbociclib (-7.0), Pyranoamentoflavone (-8.2), and Tetracycline (-7.6). Visualization of these interactions with Discovery Studio Visualizer provided insights into ligand binding within the IL-4 binding pocket, highlighting the potential for therapeutic applications of these compounds.
The evolutionary conservation profile indicated that deleterious nsSNPs tended to be located in conserved regions, further underscoring their potential impact on protein function. Using HOPE, we identified the four most detrimental mutations R139G, A118G, R112C, and R139W and analyzed their predicted effects on IL-4 structure, noting that R139W was larger than the wild type, while the other three were smaller. These mutations were found within critical domains, suggesting they may disrupt IL-4’s immune regulatory function. Studies by Gu et al. (2020) and Wei et al. (2017) have shown that compounds targeting IL-4 pathways could help mitigate the inflammatory response in diseases such as conjunctivitis. The use of tools like HOPE to evaluate the structural consequences of mutations further builds on the growing body of literature that integrates computational biology with experimental methods to elucidate the functional effects of mutations.
By identifying key regions of IL-4 affected by deleterious mutations, this study contributes to our understanding of how genetic variations influence immune function and supports the development of targeted therapies for IL-4-associated diseases, underscoring the importance of computational tools in modern drug development. This study underscores the need for further research on the pathogenicity, stability, and functional implications of nsSNPs in IL-4, with potential applications in treating conjunctivitis. In clinical settings, genetic testing and in silico analysis could guide treatment decisions, especially in the context of immune modulation, where IL-4 plays a key role in allergic infection. Advancing our understanding of nsSNPs and integrating computational and laboratory-based approaches could pave the way for new therapeutic targets and personalized medicine strategies for IL-4-associated diseases. The ultimate aim is to improve health outcomes and quality of life for patients with IL-4-related immune disorders through a collaborative effort among computational biologists, clinicians, and the pharmaceutical industry.
CONCLUSION
Using in-silico tools, 15 potentially damaging SNPs were identified, with variants like R139G, A118G, R112C, and R139W showing significant structural damage and altered protein stability, as indicated by high RMSD values and SAVESV6.1 analysis. Structural modeling using HOPE revealed that R139W might disrupt the IL-4 protein's structure, potentially making it larger than the wild type. Molecular docking studies identified several compounds, including Ioniflavone, Meridine, and Tetracycline, as having strong binding affinities to IL-4, suggesting potential therapeutic benefits. These findings highlight the significance of IL-4 genetic variants in influencing pink eye susceptibility and pave the way for future targeted therapies. However, further clinical studies are needed to assess the efficacy and safety of these compounds in treating ocular inflammation based on IL-4 genetic profiles. This study provides valuable insights for future experimental research and therapeutic approaches for immune-related diseases, including conjunctivitis.
ACKNOWLEDGMENTS
Not applicable
Author contribution
Not applicable
Funding statement
No Funding
Data Availability
The NCBI database (https://www.ncbi.nlm.nih.gov/search/all/?term=dbSNP) now contains publicly available data that was collected or analyzed during this study.
Competing interests
No conflicts of interest.
REFERENCE
Hamna Tariq*, Aniqa Amir, Muhammad Saleem, Kainat Ramzan*, Tuba Aslam, Mehmooda Asif, In-Depth In-Silico Functional, And Structural Screening Of IL-4 Gene Variants Linked with Pink Eye Infection, Int. J. Sci. R. Tech., 2024, 1 (11), 213-229. https://doi.org/10.5281/zenodo.14234050